AIM:To investigate the protective effects of gastricpentadecapeptide BPC 157 on acute and chronic gastriculcers in rats and to compare the results in therapy ofhuman gastric ulcers by different administration methods.METHODS:Gastric pentadecapeptide BPC 157 wasadministered (initial single or continuous administration)into rats either intragastrically or intramuscularly before(induced acute gastric ulcer) or after (induced chronicgastric ulcer) the applications of inducing agents,and eachanimal was sacrificed to observe the protective effects ofBPC 157 on gastric ulcers.RESULTS:Both intramuscular (im) and intragastric (ig)administration of BPC 157 could apparently reduce the ulcerarea and accelerate the healing of induced ulcer in differentmodels and the effect of im administered BPC 157 wasbetter than that of ig.The rats treated with higher dosages(400 ng/kg,800 ng/kg) of BPC 157 (im and ig) showedsignificantly less lesion (P<0.01 vs excipient or salinecontrol),the inhibition ratio of ulcer formation variedbetween 45.7% and 65.6%,from all measurements except400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05),in which the inhibition rate was 54.2%.When imadministered (800 ng/kg BPC 157) in three models,theinhibition ratio of ulcer formation was 65.5%,65.6% and59.9%,respectively,which was better than that offamotidine (its inhibition rate was 60.8%,57.2% and 34.3%,respectively).Continuous application of BPC 157 (in chronicacetate induced gastric ulcer) could accelerate rebuildingof glandular epithelium and formation of granulation tissue(P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kgvs excipient or saline control).CONCLUSION:Both im and ig administered gastricpentadecapeptide BPC 157 can apparently ameliorate acutegastric ulcer in rats and antagonize the protracted effectof acetate challenge on chronic ulcer.The effect of imadministration of BPC 157 is better than that of ig,and theeffective dosage of the former is lower than that of thelatter. AIM: To investigate the protective effects of gastric Pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods. METHODS: Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastric or intramuscularly before (induced chronic gastric ulcer) or after (induced chronic gastric ulcer) or after (induced chronic gastric ulcer) or the applications of inducing agents, and eachanimal was sacrificed to observe the protective effects ofPC 157 on gastric ulcers.RESULTS: Both intramuscular (im) and intragastric administration of BPC 157 could apparently reduce the ulcerarea and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 wasbetter than that of ig. rats treated with higher dosages (400 ng / kg, 800 ng / kg) of BPC 157 (im and ig) showedsignificantly less lesion (P <0.01 vs. excipient or saline control), the inhibition ratio of kg of BPC 157 in pylorus ligation induced model (P <0.05), in which the inhibition rate was 54.2% .When imadministered (800 ng / kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that offamotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively) .Continuous application of BPC 157 chronicacetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P <0.05 at 200 ng / kg and P <0.01 at 400 ng / kg and 800 ng / kg vs excipient or saline control) .CONCLUSION: Both im and ig administered gastric Pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer. The effect of imadministration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of thelatter.